Product category:
Laboratory and scientific books and publishing
News Release from: Frost and Sullivan | Subject: B151
Edited by the Laboratorytalk Editorial
Team on 19 February 2003
Haematology diagnostics market
resuscitates
The ubiquity of haematology tests in routine diagnostics and monitoring coupled with the rising proportion of elderly people undergoing such tests is expected to sustain growth
With a majority of haematology diagnostics tests having been in existence for over a decade, the scope for market expansion would appear constrained However, the ubiquity of haematology tests in routine diagnostics and monitoring coupled with the rising proportion of elderly people undergoing such tests is expected to sustain growth
This article was originally published on Laboratorytalk on 2 Aug 2002 at 8.00am (UK)
Related stories
Smart materials: the new frontier of technology
Analysis reveals the advances made in the development of industrial applications for smart, active, or engineered materials, including their use in smart structures
Ready for convergence?
The convergence of nanotechnology, biotechnology, information technology, and cognitive science will have a substantial impact on companies and markets in the future
Escalating uptake of newer, more expensive laboratory-based and rising adoption of haemoglobin (Hb) testing on the point of care (POC) format are forecast to further augment revenues.
The basic blood test, traditionally based on the complete blood count (CBC), has and continues to be fundamental to routine screening.
With CBC anticipated to remain among the most commonly prescribed tests, large volume sales of haematology tests and reagents are expected to persist.
Further reading
European cardiac risk assessment markers
Elevated European CHF mortality rates and introduction of premium-priced assays stimulate uptake of cardiac risk assessment markers, according to new research
Bubble bursts in defoamer market
Negative growth will force European pulp and paper defoamer suppliers to recognise commodity market, says new report
Banking on blood
The blood banking devices market will continue to post steady figures, aided by the industry's flexibility and adaptability to changing market needs and technological advancements
However, high quality, functionally advanced systems with enhanced capabilities are energising the market.
Novel analysers offer improved diagnosis due to their greater reliability, automation and sensitivity.
"Moreover, the modern haematology analyser may provide the capability of testing more recently introduced parameters, such as newer varioations of reticulocytes and platelets, which may not have been offered on the test panel of older instruments," says Alex Wong, healthcare analyst at Frost and Sullivan.
These tests are significantly costlier than the more conventional assays based on the CBC.
The expanding use of such higher priced parameters in combination with CBC + leucocyte differential analysis, which is assay is gradually supplanting CBC stand-alone tests, is expected to bolster market revenues.
However, tightening budgetary controls are likely to deter the ordering of costlier tests in the short term.
This situation will be compounded by the fact that the main haematology marker used in POC tests - haemoglobin - is already offered as part of a larger test panel currently performed on automated blood-gas analysers installed in hospitals, hence the preference will be to conduct most tests within the laboratory.
Despite these restraining trends, the European haematology diagnostics market is well positioned to deflect its imminent decline.
It is projected to surge from approximately $600 million in 2002 to over $750 million by 2009.
Not surprisingly, the laboratory is forecast to remain the principal testing arena for haematology diagnostics, widening its test locations to include smaller laboratories, alternate sites within the hospital and primary care facilities.
This market will continue to be dominated by the big five, with Beckman Coulter the number one player for now.
However, a concerted focus on haematology, continuing R and D efforts and innovative products are likely to give Sysmex and ABX the competitive edge in future.
In the smaller POC Hb test market, Hemocue is expected to maintain its monopoly.
For all these competitors, fears of a prospective market decline are gradually abating.
The growing use of costly new assays and the essential role haematology diagnostics play in routine screening and monitoring will drive market resurgence while steadily boosting revenues.
Report code B151, price ?5000.
• Frost and Sullivan: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
